Skip to main content
. 2015 Jun 1;5:123. doi: 10.3389/fonc.2015.00123

Figure 4.

Figure 4

PAR incorporation. Marked reduction in PAR was seen in all patients treated with olaparib-based therapy. Solid line represents patients treated with olaparib/cediranib and dotted line represents patients treated with olaparib alone.